The NECT Story
About Sleeping Sickness
NECT: Contributions to Its Success
ANECT: Other Studies
HAT Regional Network
NECT: challenges in The Field
Patient’s Story
Sailing Away
Brief News
DND<em>i</em>’s HAT-Related News

Chagas Disease: Agreement between Lafepe and DNDi on Safe, Easy-to-Use Treatment for Children
A partnership agreement signed on 21 July 2008 between Drugs for Neglected Diseases initiative (DNDi) and the Pharmaceutical Laboratory of Pernambuco (Lafepe) will deliver the first paediatric formulation of benznidazole, the most widely used drug for the treatment of Chagas disease, at cost and for worldwide distribution. Children infected by Chagas disease, endemic in 21 countries in Central and South America, will soon have access to a treatment tailored to their needs. The first paediatric formulation of benznidazole will be made available to patients in 2010. The drug will be sold with no profit to the institutions involved in its development, and will be available for distribution worldwide.
see also
See also:

Published by Drugs for Neglected Diseases Initiative - 15 Chemin Louis-Dunant 1202 Geneva Switzerland - Photo credits: DNDi unless otherwise stated - Editor: Sadia Kaenzig - Tel: +41 22 906 9230 - Fax: +41 22 906 9231 - www.DNDi.org